Literature DB >> 1326464

M3 muscarinic receptors mediate pepsinogen secretion via polyphosphoinositide hydrolysis in guinea pig gastric chief cells.

K Wada1, C Sakamoto, T Matozaki, H Nishisaki, Y Konda, O Nakano, K Matsuda, T Suzuki, M Nagao, M Kasuga.   

Abstract

The muscarinic receptor system involved in pepsinogen secretion from isolated guinea pig gastric chief cells was investigated by evaluating the effect of muscarinic receptor antagonists on carbamylcholine (CCh)-stimulated chief cell responses. CCh stimulated the hydrolysis of polyphosphoinositide in chief cells at the same concentrations as it stimulated pepsinogen secretion. Each of five different muscarinic receptor antagonists, atropine, pirenzepine, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), AF-DX116 and scopolamine, inhibited both pepsinogen secretion and inositol phosphate accumulation stimulated by graded concentrations of CCh. The pA2 values of the antagonists calculated from data on inositol phosphate accumulation and pepsinogen secretion (atropine = scopolamine = 4-DAMP greater than pirenzepine greater than AF-DX116) suggest that the muscarinic acetylcholine receptor in gastric chief cells is the M3 subtype. On the other hand, CCh did not affect the adenylate cyclase/cAMP signaling pathway in gastric chief cells. All pA2 values of the antagonists were also in agreement with the Ki values determined by [3H]NMS binding to chief cells. Furthermore, GTP gamma S reduced [3H]acetylcholine binding to chief cell membranes in a concentration-dependent manner. The present study, therefore, suggests that muscarinic M3 receptors, which may be coupled to a G protein, mediate pepsinogen secretion, probably by activation of the polyphosphoinositide second messenger system in guinea pig gastric chief cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326464     DOI: 10.1007/bf02777782

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  30 in total

1.  An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover.

Authors:  A Ashkenazi; J W Winslow; E G Peralta; G L Peterson; M I Schimerlik; D J Capon; J Ramachandran
Journal:  Science       Date:  1987-10-30       Impact factor: 47.728

Review 2.  Muscarinic receptor differentiation.

Authors:  F Mitchelson
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

3.  Pepsinogen secretion from dispersed chief cells from guinea pig stomach.

Authors:  J P Raufman; V E Sutliff; D K Kasbekar; R T Jensen; J D Gardner
Journal:  Am J Physiol       Date:  1984-07

4.  Pirenzepine inhibits acid and pepsinogen secretion by the isolated perfused mouse stomach.

Authors:  S A Müller-Lissner; I Szelenyi; H Engler; A L Blum
Journal:  Scand J Gastroenterol Suppl       Date:  1982

5.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

6.  Rapid formation of inositol 1,3,4,5-tetrakisphosphate following muscarinic receptor stimulation of rat cerebral cortical slices.

Authors:  I R Batty; S R Nahorski; R F Irvine
Journal:  Biochem J       Date:  1985-11-15       Impact factor: 3.857

7.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

8.  Stimulation of acid secretion and phosphoinositol production by rat parietal cell muscarinic M2 receptors.

Authors:  A Pfeiffer; H Rochlitz; A Herz; G Paumgartner
Journal:  Am J Physiol       Date:  1988-04

9.  Combined effect of phorbol ester and, A23187 or dibutyryl cyclic AMP on pepsinogen secretion from isolated gastric glands.

Authors:  C Sakamoto; T Matozaki; M Nagao; S Baba
Journal:  Biochem Biophys Res Commun       Date:  1985-08-30       Impact factor: 3.575

10.  THE ESTIMATION OF PEPSIN WITH HEMOGLOBIN.

Authors:  M L Anson; A E Mirsky
Journal:  J Gen Physiol       Date:  1932-09-20       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.